Add It Up
Immunotherapy combination treatments are the first choice for treating many advanced cancers, and more combinations are coming.
Progress Against Cancer
Immunotherapy combination treatments are the first choice for treating many advanced cancers, and more combinations are coming.
Outside the lab, Frank McCormick, PhD, FAACR, is a racecar driver, nurturing a passion he developed decades ago. (“We all need hobbies, right?” he says with a grin.) Inside the lab, he uses a...
Protein signatures in the blood could help guide physicians in choosing among different immunotherapy drugs.
Study results show stereotactic body radiation therapy could be added to standard care.
Theranostics offers the promise of combining diagnosis and treatment.
A small study finds no cancer recurrences after two years in patients who skipped breast surgery following a complete response to chemotherapy—but experts say the research is in its very early stages.
How the latest clinical therapies are helping patients and laboratory research informing future treatments.
A study found women in California were more likely to have cervical cancer diagnoses at a later stage after age 65.
Immunotherapy before surgery is proving to be an effective treatment against melanoma.
Therapeutic antibodies carry ‘payloads’ to destroy cancer cells.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now